# Voxelotor Brain Oxygenation and Neurocognitive Study

> **NCT05228821** · PHASE4 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Voxelotor Oral Tablet

## Key facts

- **NCT ID:** NCT05228821
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-08-09
- **Primary completion:** 2023-08-23
- **Final completion:** 2023-08-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study has been stopped due to Sponsor's business reasons. The termination is not a result of any safety concerns or change in the benefit-risk ratio.
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05228821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05228821, "Voxelotor Brain Oxygenation and Neurocognitive Study". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05228821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*